More Obesity Setbacks For Amylin And Takeda
This article was originally published in PharmAsia News
Executive Summary
Neither Amylin Pharmaceuticals Inc. nor its Japanese partner Takeda Pharmaceutical Company Limited has had an easy time of late with diabetes and obesity R&D, and the hold on development for their joint obesity combination therapy shows prospects aren't improving for the firms or the field